litlas
Log inCreate account

Mark M. Awad

Active 2004–2025

194
Papers
33,299
Citations
88
h-index
180
i10-index

Citations

Citations per year for Mark M. Awad1971: 3 citations1976: 2 citations2001: 2 citations2004: 2 citations2005: 8 citations2006: 14 citations2007: 10 citations2008: 10 citations2009: 23 citations2010: 19 citations2011: 24 citations2012: 8 citations2013: 27 citations2014: 64 citations2015: 116 citations2016: 161 citations2017: 215 citations2018: 338 citations2019: 1,080 citations2020: 1,741 citations2021: 1,939 citations2022: 1,760 citations2023: 1,712 citations2024: 2,774 citations2025: 1,718 citations2026: 53 citations1972–1975: no citations, so these years are not shown1977–2000: no citations, so these years are not shown2002–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,267 citing papers, 25.3% of this breakdownChina: 2,977 citing papers, 17.6% of this breakdownItaly: 949 citing papers, 5.6% of this breakdownUnited Kingdom: 823 citing papers, 4.9% of this breakdownFrance: 740 citing papers, 4.4% of this breakdownJapan: 714 citing papers, 4.2% of this breakdownGermany: 650 citing papers, 3.9% of this breakdownSpain: 595 citing papers, 3.5% of this breakdownCanada: 459 citing papers, 2.7% of this breakdownSwitzerland: 410 citing papers, 2.4% of this breakdownNetherlands: 395 citing papers, 2.4% of this breakdownSouth Korea: 374 citing papers, 2.2% of this breakdown
0%25.3%Other 20.9%

Institutions

Fields

  • Medicine70.7%
  • Biochemistry, Genetics and Molecular Biology20.3%
  • Immunology and Microbiology5.3%
  • Computer Science1.3%
  • Engineering0.7%
  • Neuroscience0.5%
  • Other1.2%

Topics

  • Cancer Immunotherapy and Biomarkers14.3%
  • Lung Cancer Treatments and Mutations10.1%
  • Lung Cancer Research Studies6.3%
  • Cancer Genomics and Diagnostics4.5%
  • Lung Cancer Diagnosis and Treatment3.9%
  • Immunotherapy and Immune Responses3.7%
  • Other57.2%

Coauthors

All papers

Open in search
  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

    Authors: Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen R. Broderick, Julie R. Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Tudor-Eliade Ciuleanu, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Janis M. Taube, Cecile Dorange, Junliang Cai, Joseph Fiore, Anthony Jarkowski, David Balli, Mark Sausen, Dimple Pandya, Christophe Y. Calvet, Nicolas Girard - New England Journal of Medicine 2022 cited by 2,558

  2. Acquired Resistance to KRAS G12C Inhibition in Cancer

    Authors: Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa L. Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Joseph O. Jacobson, Xiaoping Yang, Nicole S. Persky, David E. Root, Kristen E. Lowder, Hanrong Feng, Shannon S. Zhang, Kevin M. Haigis, Yin P. Hung, Lynette M. Sholl, Brian M. Wolpin, Julie Wiese, Jason Christiansen, Jessica Lee, Alexa B. Schrock, Lee P. Lim, Kavita Garg, Mark Li, Lars D. Engstrom, Laura Waters, J. David Lawson, Peter Olson, Piro Lito, Sai-Hong I. Ou, James G. Christensen, Pasi A. Jänne, Andrew J. Aguirre - New England Journal of Medicine 2021 cited by 1,164

  3. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

    Authors: Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach - Cancer Discovery 2018 cited by 1,604

  4. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

    Authors: Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M. Awad, Matthew D. Hellmann, Jessica J. Lin, Terence W. Friedlander, Meghan E. Bushway, Kristen N. Balogh, Tracey Sciuto, Victoria Kohler, Samantha Jane Turnbull, Rana H. Besada, Riley R. Curran, Benjamin Trapp, Julian Scherer, Asaf Poran, Dewi Harjanto, Dominik Barthelme, Ying S. Ting, Jesse Z. Dong, Yvonne Ware, Yu-Ting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan - Cell 2020 cited by 763

  5. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

    Authors: Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh, David R. Spigel, Edward B. Garon, Meghan E. Bushway, Asaf Poran, Joong Hyuk Sheen, Victoria Kohler, Ekaterina Esaulova, John Srouji, Suchitra Ramesh, Rohit Vyasamneni, Binisha Karki, Tracey Sciuto, Himanshu Sethi, Jesse Z. Dong, Melissa A. Moles, Kelledy Manson, Michael S. Rooney, Zakaria Khondker, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan - Cancer Cell 2022 cited by 222

  6. Perioperative Nivolumab in Resectable Lung Cancer

    Authors: Tina Cascone, Mark M. Awad, Jonathan Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor–Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Steven I. Blum, Mariano Provencio - New England Journal of Medicine 2024 cited by 447

  7. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

    Authors: Biagio Ricciuti, Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong, Jianjun Zhang, Michael Tolstorukov, Yvonne Y. Li, Liam F. Spurr, Andrew D. Cherniack, Gonzalo Recondo, Giuseppe Lamberti, Xinan Wang, Deepti Venkatraman, Joao V. Alessi, Victor R. Vaz, Hira Rizvi, Jacklynn V. Egger, Andrew J. Plodkowski, S. Khosrowjerdi, Subba R. Digumarthy, Hyesun Park, Nuno Vaz, Mizuki Nishino, Lynette M. Sholl, David A. Barbie, Mehmet Altan, John V. Heymach, Ferdinandos Skoulidis, Justin F. Gainor, Matthew D. Hellmann, Mark M. Awad - Journal of Thoracic Oncology 2021 cited by 367

  8. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

    Authors: Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, Mirjana Wollner, James Chih‐Hsin Yang, Julien Mazières, Francesco Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, Hye Ryun Kim, on behalf of the KEYNOTE-604 Investigators - Journal of Clinical Oncology 2020 cited by 759

  9. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

    Authors: Kari J. Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi, Erik H. Knelson, Yingtian Xie, Klothilda Lim, Paloma Cejas, Andrew Portell, Patrick H. Lizotte, Scott B. Ficarro, Shuai Li, Ting Chen, Heidi M. Haikala, Haiyun Wang, Magda Bahcall, Yang Gao, Sophia Z. Shalhout, Steffen Boettcher, Bo Hee Shin, Tran C. Thai, Margaret K. Wilkens, Michelle Tillgren, Mierzhati Mushajiang, Man Xu, Jihyun Choi, Arrien A. Bertram, Benjamin L. Ebert, Rameen Beroukhim, Pratiti Bandopadhayay, Mark M. Awad, Prafulla C. Gokhale, Paul T. Kirschmeier, Jarrod A. Marto, Fernando D. Camargo, Rizwan Haq, Cloud P. Paweletz, Kwok‐Kin Wong, David A. Barbie, Henry W. Long, Nathanael S. Gray, Pasi A. Jänne - Cancer Cell 2020 cited by 472

  10. Federated benchmarking of medical artificial intelligence with MedPerf

    Authors: Alexandros Karargyris, Renato Umeton, Micah J. Sheller, Alejandro Aristizabal, Johnu George, Anna Wuest, Sarthak Pati, Hasan Kassem, Maximilian Zenk, Ujjwal Baid, Prakash Narayana Moorthy, Alexander Chowdhury, Junyi Guo, Sahil S. Nalawade, Jacob Rosenthal, David Kanter, Maria Xenochristou, Daniel J. Beutel, Verena Chung, Timothy Bergquist, James A. Eddy, Abubakar Abid, Lewis Tunstall, Omar Sanseviero, Dimitrios Dimitriadis, Yiming Qian, Xinxing Xu, Yong Liu, Rick Siow Mong Goh, Srini Bala, Victor Bittorf, Sreekar Reddy Puchala, Biagio Ricciuti, Soujanya Samineni, Eshna Sengupta, Akshay Chaudhari, Cody Coleman, Bala Desinghu, Gregory F. Diamos, Debo Dutta, Diane Feddema, Grigori Fursin, Xinyuan Huang, Satyananda Kashyap, Nicholas D. Lane, Indranil Mallick, Pietro Mascagni, Virendra Mehta, Cassiano Ferro Moraes, Vivek Natarajan, Nikola Nikolov, Nicolas Padoy, Gennady Pekhimenko, Vijay Janapa Reddi, G. Anthony Reina, Pablo Ribalta, Abhishek Singh, Jayaraman J. Thiagarajan, Jacob Albrecht, Thomas Wolf, Geralyn Miller, Huazhu Fu, Prashant Shah, Daguang Xu, Poonam Yadav, David Talby, Mark M. Awad, Jeremy P. Howard, Michael Rosenthal, Luigi Marchionni, Massimo Loda, Jason M. Johnson, Spyridon Bakas, Peter Mattson - Nature Machine Intelligence, Nat. Mac. Intell. 2023 cited by 149

  11. Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

    Authors: Biagio Ricciuti, Xinan Wang, Joao V. Alessi, Hira Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James Lindsay, Renato Umeton, Rileen Sinha, Natalie I. Vokes, Gonzalo Recondo, Giuseppe Lamberti, Marissa Lawrence, Victor R. Vaz, Giulia C. Leonardi, Andrew J. Plodkowski, Hersh Gupta, Andrew D. Cherniack, Michael Tolstorukov, Bijaya Sharma, Kristen D. Felt, Justin F. Gainor, Arvind Ravi, Gad Getz, Kurt A. Schalper, Brian S. Henick, Patrick M. Forde, Valsamo Anagnostou, Pasi A. Jänne, Eliezer M. Van Allen, Mizuki Nishino, Lynette M. Sholl, David C. Christiani, Xihong Lin, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad - JAMA Oncology 2022 cited by 384

  12. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

    Authors: Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Amir Reza Aref, Ferdinandos Skoulidis, Grit S. Herter-Sprie, Kevin A. Buczkowski, Yan Liu, Mark M. Awad, Warren L. Denning, Lixia Diao, Jing Wang, Edwin R. Parra-Cuentas, Ignacio I. Wistuba, Margaret Soucheray, Tran C. Thai, Hajime Asahina, Shunsuke Kitajima, Abigail Altabef, Jillian D. Cavanaugh, Kevin Rhee, Peng Gao, Haikuo Zhang, Peter E. Fecci, Takeshi Shimamura, Matthew D. Hellmann, John V. Heymach, F. Stephen Hodi, Gordon J. Freeman, David A. Barbie, Glenn Dranoff, Peter S. Hammerman, Kwok‐Kin Wong - Cancer Research 2016 cited by 630

  13. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

    Authors: Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, J. Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi Hines, Jacqueline V. Aredo, Michael J. Dennis, Turja Chakrabarti, Susan C. Scott, Paolo Bironzo, Matthias Scheffler, Petros Christopoulos, Albrecht Stenzinger, Jonathan W. Riess, So Yeon Kim, Sarah B. Goldberg, Mingjia Li, Qi Wang, Yun Qing, Ying Ni, Minh Truong, Richard Lee, Biagio Ricciuti, Joao V. Alessi, Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R. Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A. Vaporciyan, George R. Blumenschein, Jianjun Zhang, Dwight H. Owen, Collin M. Blakely, Giannis Mountzios, Catherine A. Shu, Christine M. Bestvina, Marina Chiara Garassino, Kristen A. Marrone, Jhanelle E. Gray, Sandip Pravin Patel, Amy L. Cummings, Heather A. Wakelee, Juergen Wolf, Giorgio V. Scagliotti, Federico Cappuzzo, Fabrice Barlési, Pradnya D. Patil, Leylah Drusbosky, Don L. Gibbons, Funda Meric‐Bernstam, J. Jack Lee, John V. Heymach, David S. Hong, Rebecca S. Heist, Mark M. Awad, Ferdinandos Skoulidis - Cancer Discovery 2023 cited by 181

  14. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

    Authors: Catherine A. Shu, Justin F. Gainor, Mark M. Awad, Codruța Chiuzan, Claud Grigg, Aliyah Pabani, Robert F. Garofano, Mark Stoopler, Simon K. Cheng, Abby White, Michael Lanuti, F. D’Ovidio, Matthew Bacchetta, Joshua Sonett, Anjali Saqi, Naiyer A. Rizvi - The Lancet Oncology 2020 cited by 640

  15. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

    Authors: Navin R. Mahadevan, Erik H. Knelson, Jacquelyn O. Wolff, Amir Vajdi, Maria Saigí, Marco Campisi, Deli Hong, Tran C. Thai, Brandon Piel, Saemi Han, Bruce B. Reinhold, Jonathan S. Duke‐Cohan, Michael J. Poitras, Luke J. Taus, Patrick H. Lizotte, Andrew Portell, Victor Quadros, Alison Santucci, Takahiko Murayama, Israel Cañadas, Shunsuke Kitajima, Aoi Akitsu, Maya Fridrikh, Hideo Watanabe, Brendan Reardon, Prafulla C. Gokhale, Cloud P. Paweletz, Mark M. Awad, Eliezer M. Van Allen, Ana Lako, Xitao Wang, Bowen Chen, Fangxin Hong, Lynette M. Sholl, Michael Tolstorukov, Kathleen L. Pfaff, Pasi A. Jänne, Evisa Gjini, Robin Edwards, Scott J. Rodig, Ellis L. Reinherz, Matthew G. Oser, David A. Barbie - Cancer Discovery 2021 cited by 214

  16. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

    Authors: Arvind Ravi, Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino–Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer A. Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Łuksza, Alice T. Shaw, Jedd D. Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor - Nature Genetics 2023 cited by 186

  17. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

    Authors: Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad, Emiliano Calvo, Paolo A. Ascierto, Akin Atmaca, Naiyer A. Rizvi, Fred R. Hirsch, Giovanni Selvaggi, Joseph D. Szustakowski, Ariella Sasson, Ryan Golhar, Patrik Vitazka, Chang Han, William J. Geese, Scott Antonia - Cancer Cell 2018 cited by 894

  18. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    Authors: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 cited by 596

  19. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

    Authors: Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan Brennick, Ryan D. Gentzler, Carrie B. Lee, Joleen M. Hubbard, Susanne M. Arnold, James L. Abbruzzese, Salma K. Jabbour, Nataliya V. Uboha, Kevin L. Stephans, Jennifer M. Johnson, Haeseong Park, Liza C. Villaruz, Elad Sharon, Howard Streicher, Mansoor M. Ahmed, Hayley Lyon, Carrie Cibuskis, Niall J. Lennon, Aashna Jhaveri, Lin Yang, Jennifer Altreuter, Lauren Gunasti, Jason L. Weirather, Raymond H. Mak, Mark M. Awad, Scott J. Rodig, Helen X Chen, Catherine J. Wu, Arta M. Monjazeb, F. Stephen Hodi - The Lancet Oncology 2022 cited by 232

  20. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

    Authors: Tina Cascone, Mark M. Awad, J.D. Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, J. Kuzdzal, Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, M. Provencio Pulla - Annals of Oncology 2023 cited by 100

  21. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  22. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

    Authors: Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer Heng, Suzanne E. Dahlberg, Pasi A. Jänne, Suman Verma, James G. Christensen, Peter S. Hammerman, Lynette M. Sholl - Journal of Clinical Oncology 2016 cited by 688

  23. TargetingMETDysregulation in Cancer

    Authors: Gonzalo Recondo, Jianwei Che, Pasi A. Jänne, Mark M. Awad - Cancer Discovery 2020 cited by 222

  24. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

    Authors: Esther Aguilar, Biagio Ricciuti, Justin F. Gainor, Kenneth L. Kehl, Sasha Kravets, Suzanne E. Dahlberg, Mizuki Nishino, Lynette M. Sholl, Anika E. Adeni, S. Subegdjo, S. Khosrowjerdi, Rachel Peterson, Subba R. Digumarthy, C. Liu, Jennifer L. Sauter, Hira Rizvi, Kathryn C. Arbour, B.W. Carter, John V. Heymach, Mehmet Altan, Matthew D. Hellmann, Mark M. Awad - Annals of Oncology 2019 cited by 336